+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hydroxyurea therapy in children severely affected with sickle cell disease



Hydroxyurea therapy in children severely affected with sickle cell disease



Journal Of Pediatrics. 128(6): 820-828



Hypothesis: The major clinical manifestations of sickle cell disease (SCD) are hemolytic anemia, predisposition to infection, and recurrent vaso-occlusive episodes resulting in pain, organ dysfunction, or both. There has been no satisfactory treatment for children with recurrent severe painful episodes caused by SCD. Hydroxyurea is an antimetabolite drug shown in adults with SCD to increase fetal hemoglobin levels and reduce the symptoms of SCD. We hypothesized that hydroxyurea therapy in children with severe (defined as gtoreq 3 vaso-occlusive events per year) SCD could improve hematologic parameters and reduce vaso-occlusive events. Objective: To assess the safety and efficacy of hydroxyurea for the treatment of severe SCD in children. Study design: After obtaining informed consent, we initiated hydroxyurea therapy at a dosage of 10 to 20 mg/kg per day in 15 patients with severe SCD (hemoglobin SS, hemoglobin SS-alpha thalassemia, or hemoglobin S-beta-0-thalassemia). Doses were escalated as tolerated. Patients were monitored with bimonthly physical examinations and monthly laboratory measures. To assess the impact of hydroxyurea on clinical symptoms, we recorded the number of inpatient days for each patient during the period of treatment and compared it with the number of inpatient days for the 12- to 24-month period before institution of hydroxyurea therapy, using the subject as his or her own control subject. Results: Thirteen patients received hydroxyurea for a median of 24 months (range, 6 to 39 months). The mean dose of hydroxyurea was 21.4 +- 5.2 mg/kg. Treatment with hydroxyurea induced statistically significant increases in the total hemoglobin concentration, mean corpuscular volume, and percentage of hemoglobin F, and a decrease in the serum concentration of bilirubin. Toxic effects included three episodes of a reversible myelotoxic reaction, two of which required transfusion of packed erythrocytes. For the entire group, hospitalization decreased from a prehydroxyurea median of 3.9 +- 2.0 days per month to 1.1 +- 2.1 days per month of therapy (p = 0.09). For those subjects (n = 10) completing at least 1 year of treatment, the decrease in hospitalization from 4.1 +- 2.2 to 1.0 +- 1.7 days per month was significant (p = 0.03). Conclusions: In this pilot trial, hydroxyurea treatment of severe SCD in children was associated with improved hematologic parameters, acceptable toxic effects, and a trend to reduced hospitalization. Hydroxyurea appears to be a safe and potentially effective agent for the treatment of severe SCD in children. A prospective, controlled trial to investigate the efficacy of hydroxyurea in children is there-fore warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008794250

Download citation: RISBibTeXText

PMID: 8648542

DOI: 10.1016/s0022-3476(96)70335-9


Related references

Hydroxyurea therapy in severely affected children with sickle cell disease. Pediatric Research 35(4 PART 2): 163A, 1994

Hydroxyurea treatment in severely affected sickle cell disease children. Beuzard, Y, Lubin, B, Rosa, J, INSERM Colloquium; Sickle cell disease and thalassaemias: New trends in therapy, Colloque INSERM; Sickle cell disease and thalassaemias: New trends in therapy 171-172, 1995

Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin 36(4): 323-332, 2012

A pilot study of hydroxyurea treatment of severely affected children with sickle cell disease. Pediatric Research 33(4 PART 2): 147A, 1993

Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?. Pediatric Blood and Cancer 63(5): 844-847, 2016

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 19(4): 313-318, 1997

Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatric Blood and Cancer 47(7): 894-900, 2006

The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Expert Opinion on PharmacoTherapy 15(3): 325-336, 2014

Impact of hydroxyurea therapy on linear growth in children with sickle cell disease. Blood 94(10 SUPPL 1 PART 1): 416a, Nov 15, 1999

Red blood cell adhesion remains low in very young children with sickle cell disease receiving hydroxyurea therapy. Blood 94(10 SUPPL 1 PART 1): 416a, Nov 15, 1999

Effect of Hydroxyurea Therapy on Resting Energy Expenditure in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 23(9): 604-608, 2001

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. Bmc Research Notes 8: 372, 2016

Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease. Journal of Pediatric Hematology/Oncology 23(9): 604-608, 2002

Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. Journal of Pediatric Hematology/Oncology 20(1): 26-31, 1998

Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy. Journal of Stroke and Cerebrovascular Diseases 27(2): 425-431, 2017